New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording
New Webinar - View recording

Tue Jun 26 2018

ViroGates’ initial public offering of new shares was 141% oversubscribed.
As of June 26, 2018 ViroGates is listed on Nasdaq OMX First North in Denmark.

The Company’s offering of a minimum of 659,341 and a maximum of 824,175 newly issued shares at an offer price of
DKK 91 per share has been fully subscribed.
On that background, the final number of offer shares is 824,175, which will provide the Company with gross proceeds of
DKK 75.0 million.
The proceeds are to be deployed to intensify the continued commercial roll-out of the Company’s products and strengthen its product development, clinical documentation and global patent coverage.

The Company’s shares will be admitted to trading under the symbol “VIRO” (ISIN:DK0061030574) as of 26 June 2018.

More information to be found here; Investor – Announcements

+700

published suPAR studies in leading medical journals

The suPARnostic® brand consists of the following 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

Would you like to know more?

If you have any questions regarding our products or business, write to us here

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

Sign up for our newsletter

By signing up for our newsletter you will receive the latest news about our products.

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

suPARnostic® by ViroGates